Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213616 | 0.91 | RXFP1 (0.40) | MAPTTP53RXFP1KMT2AMEN1 | |
| SCHEMBL3456716 | 0.85 | PTGDR2 (0.39) | PTGDR2 | |
| SCHEMBL3456552 | 0.85 | ALDH1A1 (0.39) | PTGDR2TP53 | |
| SCHEMBL3456353 | 0.81 | PTGDR2 (0.39) | PTGDR2 | |
| SCHEMBL3456048 | 0.79 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL14498590 | 0.77 | TSHR (0.40) | KMT2AMEN1 | |
| SCHEMBL3456655 | 0.76 | ADORA1 (0.43) | PTGDR2KMT2A | |
| SCHEMBL2804576 | 0.76 | CYP2C9 (0.40) | PTGDR2MAPTTP53RXFP1KMT2A | |
| SCHEMBL14498592 | 0.75 | TSHR (0.38) | MAPTTP53KMT2AMEN1 | |
| SCHEMBL3462977 | 0.75 | CXCR2 (0.36) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | PTGDR2 167/4885MAPT 4541/4885ADORA3 959/4885 |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLPBP, PLAA | PTGDR2 175/4885MAPT 3705/4885ADORA3 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.